Compared with placebo , BI 671800 significantly reduced nasal eosinophil values ( P < .05 for all doses ) , significantly inhibited nasal inflammatory cytokine levels ( IL-4 and eotaxin , P < .05 ; 200 mg twice daily ) , and induced a dose-related reduction in ex vivo prostaglandin D2-mediated eosinophil shape change .